{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:49:51Z","timestamp":1782996591524,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n<jats:title>Hintergrund<\/jats:title>\n<jats:p>Die endokrine Orbitopathie (EO) geht mit funktionellen Einschr\u00e4nkungen und einer \u00e4sthetischen Belastung einher. Ziel der Arbeit war die Untersuchung der Versorgungssituation von Patienten mit EO an einem interdisziplin\u00e4ren Schwerpunktzentrum.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Material und Methoden<\/jats:title>\n<jats:p>Retrospektive Auswertung der interdisziplin\u00e4ren Daten hinsichtlich des klinischen Spektrums, des Versorgungsradius und der Fachrichtung zuweisender \u00c4rzte.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Ergebnisse<\/jats:title>\n<jats:p>Insgesamt wurden die Daten von 431 Patienten mit EO (Frauen: <jats:italic>n<\/jats:italic>\u202f=354, 82\u202f%; Alter [Median]: 40\u00a0Jahre; Bereich: 5\u201379) ausgewertet. 148 (35\u202f%) Patienten wurden vom Hausarzt und 123 (29\u202f%) Patienten vom Augenarzt \u00fcberwiesen. Eine Optikusneuropathie bestand bei 11 (14,3\u202f%) M\u00e4nnern und bei 21 (5,9\u202f%) Frauen (<jats:italic>p<\/jats:italic>\u202f=0,011). Zus\u00e4tzlich zur Schilddr\u00fcsenerkrankung bestanden mindestens 2 andere Autoimmunerkrankungen bei 8 (10,4\u202f%) M\u00e4nnern und bei 15 (4,3\u202f%) Frauen (<jats:italic>p<\/jats:italic>\u202f=0,079).<\/jats:p>\n<jats:p>Zwei (2,6\u202f%) M\u00e4nner und 92 (26\u202f%) Frauen nahmen psychotherapeutische Unterst\u00fctzung in Anspruch (<jats:italic>p<\/jats:italic>\u202f&lt;0,001). Anfahrtswege von 50\u202fkm oder mehr nahmen 14 (28\u202f%) M\u00e4nner und 83 (43\u202f%) Frauen mit EO in Kauf (<jats:italic>p<\/jats:italic>\u202f=0,054). Es bestand eine Assoziation einer Anfahrtsstrecke \u226550\u202fkm mit dem Bestehen weiterer Autoimmunerkrankungen (OR: 1,86; 95\u202f%-Konfidenzintervall [KI]: 1,02\u20133,39; <jats:italic>p<\/jats:italic>\u202f=0,044). Im Trend litten diese Patienten wahrscheinlicher an einer moderat-schweren oder einer sehkraftgef\u00e4hrdenden (1,78, 0,91\u20133,47; <jats:italic>p<\/jats:italic>\u202f=0,090) EO. Patienten, die einen Anfahrtsweg \u2265100\u202fkm hatten, waren eher konservativ vorbehandelt (3,78, 1,18\u201312,05; <jats:italic>p<\/jats:italic>\u202f=0,025).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Schlussfolgerungen<\/jats:title>\n<jats:p>M\u00e4nner sind im Durchschnitt schwerer von der EO betroffen, haben h\u00e4ufig weitere Autoimmunerkrankungen. Gleichzeitig sind sie der Versorgung schwerer zug\u00e4nglich. Besonders Patienten mit weiteren Autoimmunerkrankungen nehmen weite Anfahrtsstrecken an ein spezialisiertes Zentrum in Kauf.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00347-020-01050-4","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T15:14:46Z","timestamp":1581088486000},"page":"1105-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Versorgungsrelevante Daten einer interdisziplin\u00e4ren Sprechstunde f\u00fcr endokrine Orbitopathie","Healthcare relevant data from an interdisciplinary consultation for endocrine orbitopathy"],"prefix":"10.1007","volume":"117","author":[{"given":"Katharina A.","family":"Ponto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"v. d. Osten-Sacken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Elflein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Koutsimpelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"1050_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena\u00a0L, Baldeschi\u00a0L, Boboridis\u00a0K et\u00a0al (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid\u00a0J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"1050_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena\u00a0L, Baldeschi\u00a0L, Dickinson\u00a0A et\u00a0al (2008) Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273\u2013285","journal-title":"Eur J Endocrinol"},{"key":"1050_CR3","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00347-016-0239-3","volume":"113","author":"A Eckstein","year":"2016","unstructured":"Eckstein\u00a0A, Dekowski\u00a0D, Fuhrer-Sakel\u00a0D et al (2016) Graves\u2019 ophthalmopathy. Ophthalmologe 113:349\u2013364","journal-title":"Ophthalmologe"},{"key":"1050_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","volume":"93","author":"AK Eckstein","year":"2009","unstructured":"Eckstein\u00a0AK, Losch\u00a0C, Glowacka\u00a0D et\u00a0al (2009) Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol 93:1052\u20131056","journal-title":"Br J Ophthalmol"},{"key":"1050_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1055\/s-0029-1239517","volume":"71","author":"G Glaeske","year":"2009","unstructured":"Glaeske\u00a0G, Augustin\u00a0M, Abholz\u00a0H et\u00a0al (2009) Epidemiological methods for health services research. Gesundheitswesen 71:685\u2013693","journal-title":"Gesundheitswesen"},{"key":"1050_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2008-1047573","volume":"122","author":"G Kahaly","year":"1997","unstructured":"Kahaly\u00a0G, Forster\u00a0G, Pitz\u00a0S et\u00a0al (1997) Recent interdisciplinary diagnosis and therapy of endocrine orbitopathy. Dtsch Med Wochenschr 122:27\u201332","journal-title":"Dtsch Med Wochenschr"},{"key":"1050_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly\u00a0GJ, Petrak\u00a0F, Hardt\u00a0J et\u00a0al (2005) Psychosocial morbidity of Graves\u2019 orbitopathy. Clin Endocrinol 63:395\u2013402","journal-title":"Clin Endocrinol"},{"key":"1050_CR8","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly\u00a0GJ, Pitz\u00a0S, Hommel\u00a0G et\u00a0al (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J\u00a0Clin Endocrinol Metab 90:5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"1050_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly\u00a0GJ, Riedl\u00a0M, Konig\u00a0J et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a\u00a0randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 6:287\u2013298","journal-title":"Lancet Diabetes. Endocrinol."},{"key":"1050_CR10","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1210\/jc.2009-2470","volume":"95","author":"SD Lytton","year":"2010","unstructured":"Lytton\u00a0SD, Ponto\u00a0KA, Kanitz\u00a0M et\u00a0al (2010) A novel thyroid stimulating immunoglobulin bioassay is a\u00a0functional indicator of activity and severity of Graves\u2019 orbitopathy. J\u00a0Clin Endocrinol Metab 95:2123\u20132131","journal-title":"J Clin Endocrinol Metab"},{"key":"1050_CR11","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci\u00a0C, Kahaly\u00a0GJ, Krassas\u00a0GE et\u00a0al (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N\u00a0Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"1050_CR12","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1167\/iovs.15-16699","volume":"56","author":"N Matheis","year":"2015","unstructured":"Matheis\u00a0N, Grus\u00a0FH, Breitenfeld\u00a0M et al (2015) Proteomics differentiate between thyroid-associated orbitopathy and dry eye syndrome. Invest Ophthalmol Vis Sci 56:2649\u20132656","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1050_CR13","doi-asserted-by":"publisher","first-page":"E1523","DOI":"10.1210\/jc.2015-2976","volume":"100","author":"N Matheis","year":"2015","unstructured":"Matheis\u00a0N, Lantz\u00a0M, Grus\u00a0FH et al (2015) Proteomics of orbital tissue in thyroid-associated orbitopathy. J\u00a0Clin Endocrinol Metab 100:E1523\u20131530","journal-title":"J Clin Endocrinol Metab"},{"key":"1050_CR14","unstructured":"Organization WH The Right to Health. Fact Sheet No. 31"},{"key":"1050_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros\u00a0P, Hegedus\u00a0L, Bartalena\u00a0L et\u00a0al (2017) Graves\u2019 orbitopathy as a\u00a0rare disease in Europe: a\u00a0European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72","journal-title":"Orphanet J Rare Dis"},{"key":"1050_CR16","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/bjophthalmol-2015-306733","volume":"99","author":"P Perros","year":"2015","unstructured":"Perros\u00a0P, Zarkovic\u00a0M, Azzolini\u00a0C et\u00a0al (2015) PREGO (presentation of Graves\u2019 orbitopathy) study: changes in referral patterns to European Group On Graves\u2019 Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 99:1531\u20131535","journal-title":"Br J Ophthalmol"},{"key":"1050_CR17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1089\/thy.2015.0031","volume":"25","author":"KA Ponto","year":"2015","unstructured":"Ponto\u00a0KA, Binder\u00a0H, Diana\u00a0T et al (2015) Prevalence, phenotype, and psychosocial well-being in euthyroid\/hypothyroid thyroid-associated orbitopathy. Thyroid 25:942\u2013948","journal-title":"Thyroid"},{"key":"1050_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40618-015-0254-2","volume":"38","author":"KA Ponto","year":"2015","unstructured":"Ponto\u00a0KA, Diana\u00a0T, Binder\u00a0H et al (2015) Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy. J\u00a0Endocrinol Invest 38:769\u2013777","journal-title":"J Endocrinol Invest"},{"key":"1050_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","volume":"152","author":"KA Ponto","year":"2011","unstructured":"Ponto\u00a0KA, Hommel\u00a0G, Pitz\u00a0S et\u00a0al (2011) Quality of life in a\u00a0german graves orbitopathy population. Am J Ophthalmol 152:483\u2013490.e481","journal-title":"Am J Ophthalmol"},{"key":"1050_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00063-008-1112-1","volume":"103","author":"KA Ponto","year":"2008","unstructured":"Ponto\u00a0KA, Kahaly\u00a0GJ (2008) Current management of endocrine orbitopathy. Med Klin 103:717\u2013730 (quiz 729\u2013730)","journal-title":"Med Klin"},{"issue":"Suppl 2","key":"1050_CR21","first-page":"245","volume":"7","author":"KA Ponto","year":"2010","unstructured":"Ponto\u00a0KA, Kahaly\u00a0GJ (2010) Quality of life in patients suffering from thyroid orbitopathy. Pediatr Endocrinol Rev 7(Suppl 2):245\u2013249","journal-title":"Pediatr Endocrinol Rev"},{"key":"1050_CR22","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1055\/s-2008-1038911","volume":"226","author":"KA Ponto","year":"2009","unstructured":"Ponto\u00a0KA, Kahaly\u00a0GJ, Pitz\u00a0S (2009) Update on endocrine orbitopathy. Klin Monatsbl Augenheilkd 226:R13\u201328 (quiz R29\u201331)","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1050_CR23","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1016\/j.ophtha.2011.03.030","volume":"118","author":"KA Ponto","year":"2011","unstructured":"Ponto\u00a0KA, Kanitz\u00a0M, Olivo\u00a0PD et al (2011) Clinical relevance of thyroid-stimulating immunoglobulins in graves\u2019 ophthalmopathy. Ophthalmology 118:2279\u20132285","journal-title":"Ophthalmology"},{"key":"1050_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto\u00a0KA, Merkesdal\u00a0S, Hommel\u00a0G et\u00a0al (2013) Public health relevance of Graves\u2019 orbitopathy. J\u00a0Clin Endocrinol Metab 98:145\u2013152","journal-title":"J Clin Endocrinol Metab"},{"key":"1050_CR25","first-page":"283","volume":"106","author":"KA Ponto","year":"2009","unstructured":"Ponto\u00a0KA, Pitz\u00a0S, Pfeiffer\u00a0N et\u00a0al (2009) Quality of life and occupational disability in endocrine orbitopathy. Dtsch Arztebl Int 106:283\u2013289","journal-title":"Dtsch Arztebl Int"},{"key":"1050_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/cei.12395","volume":"178","author":"KA Ponto","year":"2014","unstructured":"Ponto\u00a0KA, Schuppan\u00a0D, Zwiener\u00a0I et al (2014) Thyroid-associated orbitopathy is linked to gastrointestinal autoimmunity. Clin Exp Immunol 178:57\u201364","journal-title":"Clin Exp Immunol"},{"key":"1050_CR27","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith\u00a0TJ, Kahaly\u00a0GJ, Ezra\u00a0DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N\u00a0Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"key":"1050_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1089\/thy.2010.1634","volume":"20","author":"MN Stan","year":"2010","unstructured":"Stan\u00a0MN, Bahn\u00a0RS (2010) Risk factors for development or deterioration of Graves\u2019 ophthalmopathy. Thyroid 20:777\u2013783","journal-title":"Thyroid"},{"key":"1050_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00347-015-0212-6","volume":"113","author":"I Strempel","year":"2016","unstructured":"Strempel\u00a0I (2016) Endocrine ophthalmopathy. A visible psychophysical complaint. Ophthalmologe 113:126\u2013130","journal-title":"Ophthalmologe"},{"key":"1050_CR30","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda\u00a0ML, Piantanida\u00a0E, Liparulo\u00a0L et\u00a0al (2013) Prevalence and natural history of Graves\u2019 orbitopathy in a\u00a0large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a\u00a0single center. J\u00a0Clin Endocrinol Metab 98:1443\u20131449","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"1050_CR31","first-page":"250","volume":"7","author":"WM Wiersinga","year":"2010","unstructured":"Wiersinga\u00a0WM (2010) Combined thyroid eye clinic: the importance of a\u00a0multidisciplinary health care in patients with Graves\u2019 orbitopathy. Pediatr Endocrinol Rev 7(Suppl 2):250\u2013253","journal-title":"Pediatr Endocrinol Rev"},{"key":"1050_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/01676830500192167","volume":"24","author":"WM Wiersinga","year":"2005","unstructured":"Wiersinga\u00a0WM (2005) The philosophy of Graves\u2019 ophthalmopathy. Orbit 24:165\u2013171","journal-title":"Orbit"},{"key":"1050_CR33","first-page":"359","volume":"26","author":"WM Wiersinga","year":"2012","unstructured":"Wiersinga\u00a0WM (2012) Quality of life in Graves\u2019 ophthalmopathy. Best practice & research. Clin Endocrinol Metab 26:359\u2013370","journal-title":"Clin Endocrinol Metab"},{"key":"1050_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/eje.1.02230","volume":"155","author":"WM Wiersinga","year":"2006","unstructured":"Wiersinga\u00a0WM, Perros\u00a0P, Kahaly\u00a0GJ et\u00a0al (2006) Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387\u2013389","journal-title":"Eur J Endocrinol"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01050-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-020-01050-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-020-01050-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:01:21Z","timestamp":1612821681000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-020-01050-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1050"],"URL":"https:\/\/doi.org\/10.1007\/s00347-020-01050-4","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"7 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.A.\u00a0Ponto, S.\u00a0v.d.\u00a0Osten-Sacken, H.\u00a0Elflein, D.\u00a0Koutsimpelas, N.\u00a0Pfeiffer und G.J.\u00a0Kahaly erkl\u00e4ren, dass kein Interessenkonflikt im Sinne der Richtlinien des International Committee of Medical Journal Editors besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen wurden im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Personen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}